FDA approves Roche’s Xofluza for Influenza post-exposure prophylaxis
Roche has announced that the U.S. FDA has granted supplemental New Drug Application (sNDA) approval for Xofluza, the first single-dose
Read moreRoche has announced that the U.S. FDA has granted supplemental New Drug Application (sNDA) approval for Xofluza, the first single-dose
Read moreModerna announced today that the European Commission has approved an agreement to buy 80 million doses of mRNA-1273, Moderna’s COVID-19
Read moreAstraZeneca announced today, that interim trial data has shown it’s COVID-19 vaccine candidate AZD1222, developed in collaboration with the University
Read moreModerna announced its vaccine candidate against COVID-19 named mRNA-1273, has met Phase 3 study statistical criteria with a vaccine efficacy
Read moreGovernments around the world are scrambling to prepare for the rollout of the Pfizer and BioNTech COVID-19 vaccine, with many
Read morePfizer and BioNTech announced this week that they have reached an agreement with the European Commission to supply 200 million
Read morePfizer and BioNTech have announced their mRNA-based vaccine candidate for COVID-19, tested in a Phase 3 study involving 43,538 participants,
Read moreNovavax has announced the expansion of its Gaithersburg, Maryland campus to support global vaccine development through the addition of two
Read moreZejula (niraparib), developed by pharma giant GSK, has become the first polymerase (PARP) inhibitor approved as monotherapy in the EU for
Read moreSanofi and GSK plan to make available to the Gavi lead COVAX Facility 200 million doses of their adjuvanted recombinant
Read more